Loading...
Tighter Gene Therapy Regulations And Safety Risks Will Challenge Neurology Pipeline Yet Offer Long-Term Promise
n/a
n/a
AnalystLowTarget's Fair Value
n/a
1Y
46.1%7D
14.3%1Y
46.1%7D
14.3%You can edit this narrative until Dec 15 1:05 PM. Then, changes will post as Updates.